Meng Yiting, Feng Jin, Yang Jianghui, Yin Hongfang
Department of Pathology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University Beijing 102218, China.
Am J Cancer Res. 2024 Aug 25;14(8):3994-4003. doi: 10.62347/FPUJ8382. eCollection 2024.
Endometrial carcinoma (EC) is one of the three major malignancies of the female reproductive organs. With intense research of tumor molecular mechanisms and development of precision medicine in recent years, the traditional pathomorphological classification fails to meet the needs of clinical diagnosis and treatment for EC. This study aims to analyze the correlation of different Proactive Molecular Risk Classifier for Endometrial Cancer molecular subtypes with lymph node metastasis (LNM) and other clinical features in EC. 120 treatment-naive EC patients with surgery were enrolled in this study. The molecular subtypes of these patients were classified as follows by Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular subtyping: mismatch repair deficiency (MMRd) in 22 cases (18.33%), polymerase epsilon exonuclease domain mutation (POLE EDM) in 2 cases (1.67%), p53 wild-type (p53-wt) in 64 cases (53.33%), and p53 abnormal (p53-abn) in 32 cases (26.67%). The clinicopathological features of 120 patients were retrospectively analyzed. Statistical significance was identified among the four molecular subtypes in terms of histological classification, International Federation of Gynecology and Obstetrics (FIGO) staging, pathological grading, and LNM. Among the enrolled cases, 26 had LNM and 94 had no lymph node involvement. According to the multivariate Logistic regression analysis, p53 wt (P=0.008, OR=0.078, 95% CI: 0.012-0.510) was a protective factor for LNM in EC patients, while poorly differentiated histology (P=0.001, OR=15.137, 95% CI: 3.013-76.044) was a risk factor. ProMisE classification system, being more objective and reproducible, can provide an important reference for preoperative decision-making. The patients with p53 wt by ProMisE had a low risk of LNM in preoperative diagnostic curettage specimens, while there was a higher risk of LNM among the patients with poorly differentiated EC.
子宫内膜癌(EC)是女性生殖器官三大主要恶性肿瘤之一。近年来,随着对肿瘤分子机制的深入研究以及精准医学的发展,传统的病理形态学分类已无法满足EC临床诊断和治疗的需求。本研究旨在分析子宫内膜癌不同主动分子风险分类器分子亚型与EC患者淋巴结转移(LNM)及其他临床特征之间的相关性。本研究纳入了120例未经治疗且接受手术的EC患者。这些患者的分子亚型根据子宫内膜癌主动分子风险分类器(ProMisE)分子分型分为:错配修复缺陷(MMRd)22例(18.33%),聚合酶ε外切酶结构域突变(POLE EDM)2例(1.67%),p53野生型(p53-wt)64例(53.33%),p53异常(p53-abn)32例(26.67%)。对120例患者的临床病理特征进行回顾性分析。在组织学分类、国际妇产科联盟(FIGO)分期、病理分级和LNM方面,四种分子亚型之间存在统计学差异。在纳入的病例中,26例有LNM,94例无淋巴结受累。根据多因素Logistic回归分析,p53野生型(P=0.008,OR=0.078,95%CI:0.012-0.510)是EC患者LNM的保护因素,而低分化组织学(P=0.001,OR=15.137,95%CI:3.013-76.044)是危险因素。ProMisE分类系统更客观且可重复,可为术前决策提供重要参考。ProMisE分类为p53野生型的患者在术前诊断性刮宫标本中LNM风险较低,而低分化EC患者中LNM风险较高。